

Organised by



Inserm

LE STUDIUM
Loire Valley
Institute for Advanced Studies

ISyCatC IV

In honor of Prof. Christine Pham

Contact / website

✉ brice.korkmaz@inserm.fr

🌐 isycatc2024.sciencesconf.org

PROGRAM

17 > 19 April 2024

Tours, France

Localisation of the congress

Hôtel Oceania L'Univers Tours
5 Bd Heurteloup 37000 Tours
France

With the support of



wednesday April 17th

16:00	Registration	10:05	
17:45	Welcome cocktail reception		
19:00	OPENING AND WELCOME SPEECH		
	B. Korkmaz [France]		
	• International cathepsin C consortium [Icat-CC]		
19:05	C. Beaumont Université de Tours [France]	10:25 11:00	
	<i>Vice-présidente en charge de la recherche</i>		
19:10	M. Si-Tahar Inserm [France]	11:00	
	<i>Représentant régional</i>		
19:15	S. Gabillet Le Studium [France]	11:20	
	<i>General Secretary, Loire Valley Institute for Advanced Studies</i>		
19:20	B. Korkmaz [France]	11:40	
	• Cathepsin C inhibition as a potential therapeutic approach in neutrophil-mediated inflammatory disease		
	• Prof. Christine Pham's biography		
	<i>Award ceremony</i>		
20:00	KEYNOTE LECTURE		
	J. Chalmers [United Kingdom]		
	• Clinical trials with cathepsin C inhibitors		
	<i>Discussion on pathophysiology/treatments</i>		

thursday April 18th

09:00	Session 1		
	PHYSIOLOGY AND PATHOPHYSIOLOGY OF CATHEPSIN C		
	Chair: G. Lalmanach [France]		
09:00	M. Novinec [Slovenia]	14:30	
	• Exploring the impact of oligomeric state on cathepsin C activity		
09:20	A. Aghdassi [Germany]	14:50	
	• Intracellular vesicle transport and involvement of cathepsin C in acute pancreatitis		
09:40	C. Pham [USA]	15:30	
	• Cathepsin C, a historical perspective		
		15:50 16:10	

Session 2

PHYSIOLOGY AND PATHOPHYSIOLOGY OF CATHEPSIN C TARGETS

Chair: A. Ö. Yildirim [Germany]

10:05	P. McDonald [Canada]		
	• Cathepsin C and its substrates vs neutrophil functional responses		
	Coffee break		
	T. Secher [France]		
	• The proteolytic airway environment associated to pneumonia acts as a biological barrier for antibody treatment		
	N. Leborgne [Switzerland]		
	• Neutrophil serine proteases degrade SARS-CoV-2 spike protein and reduce virus replication and inflammation <i>in vivo</i>		
	R. Stockley [UK]		
	• Alpha-1 antitrypsin deficiency the path from antiproteases to clinical management		

Selected 5 min Talks :

- C.H. Chen** [UK] : *A novel in vitro cellular model for assessing neutrophil proteinase biomarkers in chronic lung disease*
- E. Johnson** [UK] : *The relationship between neutrophil proteins, clinical severity and the airway microbiome in bronchiectasis*

Lunch Buffet

14:30	R. Vanbever [Belgium]		
	• Assessment of neutrophil elastase protein inhibitors in muco-obstructive lung diseases		
14:50	U. Specks [USA]		
	• PR3-ANCA interactions with its target antigen: what can they tell us about the disease		
15:10	M. Zoidakis [Greece]		
	• Proteomics for characterization of cathepsin C target serine proteases		
15:30	L. Hellman [Sweden]		
	• Mast cell proteases: <i>key players in inflammation and tissue homeostasis</i>		

Coffee break

Session 3

PHARMACOLOGICAL TARGETING OF CATHEPSIN C

Chair: M. Sieńczyk [Poland]

16:10	R. Domain [France]		
	• Stability and activation of neutrophil elastase-related serine protease zymogens in myelomonocytic cells		
16:30	J. Cichy [Poland]		
	• Targeting cathepsin C in the context of neutrophil function		
17:00	I. Borek [Austria]		
	• Inactivation of cathepsin C in pulmonary arterial hypertension		
17:20	S. Korkmaz-Icöz [Germany]		
	• Role of neutrophil serine proteases in ischemia/reperfusion injury following heart transplantation		

Gala Dinner

friday April 19th

09:00	M. Rhimi [France]		
	• Inactivation of cathepsin C in inflammatory bowel diseases		
09:20	K.J. Chen [USA]		
	• The role of a cathepsin C inhibitor in lupus nephritis		
09:40	I. Couillin [France]		
	• Consequences of cathepsin C inactivation in cigarette smoke or ozone-induced lung inflammation in mice		
10:00 10:20	Coffee break		
10:20	M. Long [UK]		
	• The cathepsin C inhibitor brensocatib reduces airway azurocidin-1 levels in bronchiectasis		
10:40	S. Kreideweiss & M. Schlepütz [Germany]		
	• Preclinical and phase I development of the novel oral cathepsin C inhibitor BI 1291583		
11:00	G. Szabo [Germany]		
	• Design of clinical trials evaluating cathepsin C inhibition in heart transplantation		
11:20	C. Taggart [UK]		
	• Pharmacological inhibition of cathepsin S and consequences for cathepsin C activation		
11:40	D. Scherman [France]		
	• Foundation for Rare Diseases [FFRD]		
12:00 14:00	Lunch Buffet		